Matching-adjusted indirect comparison (MAIC) of deucravacitinib versus adalimumab for the treatment of patients with moderate to severe plaque psoriasis over 2 years

• DOI: 10.25251/skin.7.supp.112
• Publication Date: 2023-03-13T11:17:44Z
• Authors: April W. Armstrong; Sang Hee Park; Vardhaman Patel; Malcolm Hogan; Wei-Jhih Wang; David Davidson; Viktor Chirikov

Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved in the US for treatment of adults with moderate to severe plaque psoriasis (PsO). A previous indirect study showed comparable efficacy between deucravacitinib and first-generation biologics at week 52. The objective this was compare long-term that adalimumab based on extension (LTE) trials, after adjusting differences patient characteristics baseline. 
 Methods: Open-label LTE trials were feasible comparison identified each (deucravacitinib: POETYK PSO-LTE [NCT04036435]; adalimumab: REVEAL [NCT00195676]). Patients who initially randomized placebo switched continuous active Week 16 selected as cohorts due comparability design outcomes interest. prior excluded from cohort. primary outcome PASI 75 112 since randomization secondary 52 90 Weeks 112; missing data imputed using last observation carried forward (LOCF) method. Matching-adjusted conducted where individual patient-level reweighted achieve balance summary baseline trial: age, sex, race, weight, duration psoriasis, body surface area affected, history, 75/90 responses 16. Sensitivity analyses explored effect or not well history psoriatic arthritis patient's overall severity disease.
 Results: (N=329) average older, lower but more systemic exposure, higher score response than those (N=345). After adjustment, two mitigated. Results adjusted rate patients treated compared weeks placebo: 75= 67.2% vs 54% (mean difference [95% CI]= 13.2% [4, 22.5]); 90= 41.3% 34% (7.3% [-2, 16.7]). Adjusted similar cohorts. sensitivity confirmed base case findings.
 Conclusion: This analysis suggests had better highlights therapeutic role deucravacitinib.